George Davis, MD
Cardiovascular Disease · Wilmington, DENPI 1346210887
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $507 and has fallen 52.4% since, to $241 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in DE, where the typical reported total is $2,459.
Across 124 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$484
- Novartis$400
- Esperion Therapeutics, Inc.$241
- Johnson & Johnson$171
- Pfizer$147
- Biotronik Inc.$147
- plus $612 from 11 others
What the payments were for
- Food & beverage$2,203100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 27 | $484 |
| Novartis | 29 | $400 |
| Esperion Therapeutics, Inc. | 8 | $241 |
| Johnson & Johnson | 11 | $171 |
| Pfizer | 9 | $147 |
| Biotronik Inc. | 2 | $147 |
| E.r. Squibb & Sons, L.L.C. | 9 | $128 |
| Kowa Pharmaceuticals America, Inc. | 7 | $95 |
| Merck | 5 | $82 |
| Lilly USA, LLC | 4 | $73 |
| Amgen | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $53 |
| AstraZeneca | 3 | $49 |
| GSK | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$125
- NEXLETOL$125
- AMVIA EDGE$123
How this compares
$2,203 in reported general payments places this provider in the 45th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 464 | $640,887 |
| XareltoRivaroxaban | 73 | $99,548 |
| Repatha SureclickEvolocumab | 97 | $76,555 |
| MultaqDronedarone Hcl | 22 | $38,126 |
| BrilintaTicagrelor | 20 | $23,867 |
| NexletolBempedoic Acid | 24 | $20,647 |
| Nebivolol Hcl | 153 | $13,355 |
| Rosuvastatin Calcium | 643 | $13,104 |
| EntrestoSacubitril/Valsartan | 12 | $8,121 |
| Praluent PenAlirocumab | 17 | $8,082 |
| Metoprolol Succinate | 349 | $6,522 |
| Enoxaparin Sodium | 13 | $6,093 |
| Ranolazine ErRanolazine | 49 | $4,162 |
| Valsartan | 90 | $3,874 |
| Atorvastatin Calcium | 244 | $3,730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $147 | $640,887464 claims |
| Johnson & JohnsonXarelto | $171 | $99,54873 claims |
| AstraZenecaBrilinta | $49 | $23,86720 claims |
| Esperion Therapeutics, Inc.Nexletol | $241 | $20,64724 claims |
| NovartisEntresto | $400 | $8,12112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Wilmington
- Vinay HosmaneWilmington$256K
- Hamid DeliriWilmington$10K
- Piamsook AngkeowWilmington$4K
- Andra PopescuWilmington$3K
- Yolanda HendleyWilmington$3K
- Vincent MarmoWilmington$2K
- Wasif QureshiBear$122K
- Rajinder PrasadLewes$72K
- Ehtasham QureshiLewes$52K
- Edward GoldenbergNewark$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.